UNTERNEHMENSDATEN
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha- …
KURSVERLAUF
1T
+0,9 %
1W
-1,1 %
1M
+12,3 %
6M
+64,7 %
YTD
+56,7 %
1J
+143,2 %
2J
+239,7 %
5J
+190,4 %
10J
–
FRAG DIE AGENTEN ZU PTGX
Keine Anlageberatung. Für die vollständige Analyse-Übersicht: zur Analyse-Seite →
ANALYSTEN-EINSCHÄTZUNG
KURSZIEL TIEF
110,00 $
KONSENS
134,83 $
MEDIAN
133,00 $
KURSZIEL HOCH
165,00 $
0
STRONG BUY
25
BUY
1
HOLD
0
SELL
0
STRONG SELL
26
GESAMT · Buy
| DATUM | ANALYSTENHAUS | RATING | AKTION |
|---|---|---|---|
| 14.07.2026 | Barclays | Overweight | maintain |
| 07.07.2026 | Truist Securities | Buy | maintain |
| 06.05.2026 | Citizens | Market Outperform | maintain |
| 06.05.2026 | Wedbush | Outperform | maintain |
| 15.04.2026 | Truist Securities | Buy | maintain |
| 07.04.2026 | Clear Street | Buy | maintain |
| 19.03.2026 | Citigroup | Buy | maintain |
| 19.03.2026 | JP Morgan | Overweight | maintain |
KENNZAHLEN
KGV
-75,94
KBV
13,59
EV/EBITDA
-75,63
EIGENKAPITALRENDITE
0,6 %
NETTOMARGE
6,7 %
VERSCHULDUNG (D/E)
0,01
DIVIDENDENRENDITE
0 %
STAND
31.03.2026
FREE FLOAT & LIQUIDITÄT
STREUBESITZ
81,6 %
AKTIEN IM STREUBESITZ
52.492.872
Ø TAGESVOLUMEN (30T)
828.047
INVESTIERTE FONDS
| FONDS / INSTITUTION | ANTEILE | VERÄNDERUNG | STAND |
|---|---|---|---|
| NAN FUNG TRINITY (HK) Ltd | 160.670 | +0 | 30.06.2026 |
| MOODY ALDRICH PARTNERS LLC | 59.601 | +5.708 | 30.06.2026 |
| NEW YORK STATE TEACHERS RETIREMENT SYSTEM | 49.550 | +2.126 | 30.06.2026 |
| State of Alaska, Department of Revenue | 28.084 | -9.063 | 30.06.2026 |
| Louisiana State Employees Retirement System | 26.500 | +400 | 30.06.2026 |
Keine Anlageberatung. Vergangene Wertentwicklung ist kein Indikator für zukünftige Ergebnisse.